N. Ahluwalia - Vertex Pharmaceuticals

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 11 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

133 Long-term safety and efficacy of elexacaftor-tezacaftor-ivacaftor in children aged 6 and older with cystic fibrosis and at least one F508del allele: 144-week results of an open-label extension study

C. Wainwright,S. McColley, P. McNally, M. Powers,F. Ratjen,J. Rayment, G. Retsch-Bogart, E. Roesch,N. Ahluwalia, C. Chu, P. Menon, T. Weinstock,

Journal of Cystic Fibrosis (2023): S70-S71

引用0浏览0引用

Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study

Cori L. Daines,Elizabeth Tullis,Stefano Costa,Rachel W. Linnemann,Marcus A. Mall,Edward F. McKone,Deepika Polineni,Bradley S. Quon,Felix C. Ringshausen,Steven M. Rowe,Hiran Selvadurai,Jennifer L. Taylor-Cousar,

The European respiratory journalno. 6 (2023): 2202029-2202029

引用0浏览0WOS引用

WS16.03 Registry-based study of people with cystic fibrosis (pwCF) treated with elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA): Up to 2 years of real-world outcome data

J.K. Bower, C.-Y. Chang,G. Sahota, A. Chin,N. Ahluwalia,C. Chu, T.G. Weinstock, J. Ostrenga,N. Regenfuß, L. Naehrlich

Journal of Cystic Fibrosis (2023): S30-S30

引用0浏览0引用

137 Long-term safety and efficacy of elexacaftor-tezacaftor-ivacaftor in children aged 2 and older with cystic fibrosis and at least one F508del allele: 48-week results of an open-label extension study

J. Goralski, C. Daines, J. Pittman,J. Rayment, P. Robinson, R. Thursfield, F. Stehling,F. Ratjen,N. Ahluwalia, C. Chu, P. Menon, T. Weinstock,

Journal of Cystic Fibrosis (2023): S73-S73

引用0浏览0引用

170 Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from an open-label extension study

M. Griese,E. Tullis, M. Chilvers, B. Fabrizzi,R. Jain,J. Legg,M. Mall,E. McKone,D. Polineni, K. Poplawska, P. Robinson, J. Taylor-Cousar,

Journal of Cystic Fibrosis（2022）

引用0浏览0引用

185 Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating or residual function mutation

J. Chmiel, P.J. Barry, C. Colombo, E. De Wachter, I. Fajac,M. Mall, K. McBennett,E. McKone, P. Mondejar-Lopez,B. Quon, B. Ramsey,P. Robinson,

Journal of Cystic Fibrosis (2022): S108-S109

引用0浏览0引用

163 Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children 6 years and older with cystic fibrosis and at least one F508del alleles: 96-week interim results from an open-label extension study

C. Wainwright, S. McColley, P. McNally, M. Powers,F. Ratjen,J. Rayment, G. Retsch-Bogart, E. Roesch,N. Ahluwalia, A. Chin,C. Chu, M. Lu,

Journal of Cystic Fibrosis（2022）

引用0浏览0引用

169 A phase 4, fully decentralized clinical trial to evaluate physical activity and cough frequency in patients with cystic fibrosis using wearable technology

A. Braun,N. Simmonds, P. Barry,J. Davies, M. Egan, A. Lapey,D. Peckham,N. Withers,N. Ahluwalia, K. Goguen,M. Jennings, Y. Lou,

Journal of Cystic Fibrosis（2022）

引用0浏览0引用

Triple Therapy for Cystic Fibrosis Phe508del–Gating and –Residual Function Genotypes

Peter J. Barry,Marcus A. Mall,Antonio Álvarez,Carla Colombo,Karin M. de Winter-de Groot,Isabelle Fajac,Kimberly A. McBennett,Edward F. McKone,Bonnie W. Ramsey,Sivagurunathan Sutharsan,Jennifer L. Taylor-Cousar,Elizabeth Tullis,

New England Journal of Medicineno. 9 (2021): 815-825

引用0浏览0引用

562: Elexacaftor/tezacaftor/ivacaftor in children aged 6 and older with cystic fibrosis and at least 1 F508del allele: Interim results from a Phase 3 open-label extension study

F. Ratjen,H. Escobar, J. Gaffin,S. McColley, E. Roesch, F. Ruiz, C. Wainwright,N. Ahluwalia,C. Chu,S. Noel, S. Moskowitz, D. Waltz,

Journal of Cystic Fibrosis（2021）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn